Search Results
Your search for The,The matches 32862 pages
Showing 201 - 250Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer
Managing patients with lung cancer in the current era of an increasing array of systemic treatments has become a complex balancing act of trying to improve outcomes and survival from a cancer perspective while taking the necessary treatment and monitoring steps for cardioprotection. With few...
Avelumab Plus Axitinib in Mismatch Repair–Proficient Recurrent or Persistent Endometrial Cancer
The combination of avelumab and axitinib may be effective in patients with mismatch repair–proficient recurrent or persistent endometrial cancer, according to new findings presented by Lee et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. Background...
Liquid Biopsy May Help Predict Outcomes in Patients With Gastroesophageal Cancers Following Immunotherapy
Monitoring circulating tumor DNA (ctDNA) levels with liquid biopsies could help physicians accurately assess treatment responses and predict future prognoses in patients with operable esophageal or gastroesophageal junction cancer receiving an immunotherapy doublet, according to a recent study...
Mansoor R. Mirza, MD, on Endometrial Cancer: Update on Combination Regimen of Dostarlimab, Chemotherapy, and Niraparib
Mansoor R. Mirza, MD, of Copenhagen University Hospital, discusses follow-up results from the RUBY trial, showing that, for patients with primary advanced or recurrent endometrial cancer, dostarlimab-gxly plus chemotherapy followed by dostarlimab-gxly plus niraparib improved progression-free...
Brian M. Slomovitz, MD, on Cervical Cancer: Update on Tisotumab Vedotin vs Chemotherapy
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, Miami Beach, discusses additional phase III data from the innovaTV 301 trial, which showed that in patients with previously treated recurrent or metastatic cervical cancer, tisotumab vedotin-tftv was more efficacious than chemotherapy as...
FDA Grants Accelerated Approval to Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the multitarget kinase inhibitor (Iclusig) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). PhALLCON Efficacy was evaluated in...
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening
In the BLUE-C study—reported in The New England Journal of Medicine—Imperiale et al found that a next-generation multitarget stool DNA test showed high sensitivity for colorectal cancer and high specificity for advanced neoplasia compared with colonoscopy screening. Study Details The U.S....
Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in the Journal of Clinical Oncology by Jason J. Luke, MD, FACP, and colleagues, the final prespecified analysis of distant metastasis–free survival in the phase III KEYNOTE-716 trial showed continued benefit with adjuvant pembrolizumab vs placebo in patients with resected stage IIB or...
Lillian L. Siu, MD, FRCPC, FASCO, FAACR, Named 2024–2025 AACR President-Elect
The American Association for Cancer Research (AACR) announced that its members have elected Lillian L. Siu, MD, FRCPC, FASCO, FAACR, as the 2024–2025 President-Elect of the AACR. Professional and Research Background Dr. Siu currently serves as Professor of Medicine at the University of Toronto; as ...
Hormonal Therapy Plus SBRT for Advanced Prostate Cancer
Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer, according to a recent study published by Nikitas et al in...
Performance of cfDNA Blood-Based Test for Colorectal Cancer Screening
In the ECLIPSE study—reported in The New England Journal of Medicine—Chung et al found that a cell-free DNA (cfDNA) blood-based test had high sensitivity for colorectal cancer and high specificity for advanced neoplasia in colorectal cancer screening compared with colonoscopy. Study Details The...
Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC
Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) received a first-line combination regimen of pembrolizumab plus...
Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer
Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair–proficient (pMMR) advanced or ...
Localized or Advanced Prostate Cancer: Short- or Longer-Term Relugolix Plus Radiotherapy
In an analysis reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that treatment with relugolix was associated with rapid achievement of sustained castration in patients with localized or advanced prostate cancer who were also receiving radiotherapy. Study Details The analysis...
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
The artificial intelligence (AI)-based chatbot ChatGPT version 3.4 may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented by Patel et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on...
Exploring the Genetic Link Between Colorectal Cancer and Meat Consumption
Researchers have identified two genetic markers that may illuminate the association between red and/or processed meat consumption and the risk of colorectal cancer, according to a novel study published by Stern et al in Cancer Epidemiology, Biomarkers & Prevention. Background Previous studies...
SABR for Patients With Primary Kidney Cancer Not Undergoing Resection
In a phase II study (FASTRACK II) reported in The Lancet Oncology, Shankar Siva, MBBS, PhD, and colleagues found that stereotactic ablative body radiotherapy (SABR) was effective in patients with primary kidney cancer who did not undergo resection. Study Details Seventy patients were enrolled in...
H pylori Infection: Risk of Colorectal Cancer and Colorectal Cancer–Related Mortality
In a study among U.S. veterans reported in the Journal of Clinical Oncology, Shah et al found that Helicobacter pylori infection was associated with an increased risk of colorectal cancer and cancer-related death; additionally, treated H pylori infection was associated with reduced cancer incidence ...
Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL
On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...
FDA Approves Tislelizumab for Previously Treated Patients With Advanced Esophageal Cancer
On March 14, the U.S. Food and Drug Administration (FDA) approved the humanized immunoglobulin G4 anti–PD-1 monoclonal antibody tislelizumab-jsgr (Tevimbra) as monotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not...
Enfortumab Vedotin Plus Pembrolizumab Yields Benefit in Key Subgroups With Advanced Urothelial Cancer
The combination of the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab achieved favorable rates of progression-free survival, overall survival, and objective responses compared with chemotherapy among key subgroups of patients with previously...
p16-Positive Oropharyngeal Cancer: Surrogate Endpoints for Overall Survival in Clinical Trials
In a retrospective review reported in The Lancet Oncology, Gharzai et al identified intermediate clinical endpoints that may serve as surrogates for overall survival in trials assessing definitive treatment of patients with p16-positive oropharyngeal squamous cell carcinoma. Study Details The...
Trends in Breast Cancer Diagnoses During the COVID-19 Pandemic
Investigators may have identified a decrease in newly diagnosed breast cancer cases during the first year of the COVID-19 pandemic, according to a recent study published by Fefferman et al in Cancer Medicine. The findings highlight that breast cancer was not immune to pandemic-related stressors and ...
Previously Untreated Advanced Urothelial Cancer: Antibody-Drug Conjugate Plus PD-1 Inhibitor
As reported in The New England Journal of Medicine by Thomas Powles, MD, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody-drug conjugate enfortumab vedotin-ejfv and the PD-1 inhibitor pembrolizumab improved progression-free and overall survival vs...
SABR in Patients With Early NSCLC and Interstitial Lung Disease
In a study reported in JAMA Oncology, David A. Palma, MD, PhD, and colleagues found that stereotactic ablative radiotherapy (SABR) met criteria for efficacy and toxicity in patients with early non–small cell lung cancer (NSCLC) and interstitial lung disease (ILD). As stated by the investigators,...
From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research
Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...
Nab-sirolimus in Advanced Malignant Perivascular Epithelioid Cell Tumors: AMPECT Trial Final Analysis
As reported in the Journal of Clinical Oncology by Wagner et al, final analysis of the phase II AMPECT trial has shown a median duration of response of more than 3 years in patients with advanced malignant perivascular epithelioid cell tumors treated with nab-sirolimus. The primary analysis of the...
ACS and Flatiron Health Announce Recipients of Fourth Annual Real-World Data Impact Awards
The American Cancer Society (ACS) and Flatiron Health announced the recipients of the 2023 Real-World Data Impact Awards, which will support clinically relevant research regarding the treatment of and outcomes for patients with cancer. 2023 marks the fourth year of the joint grant-making program,...
Novel Dual-Target CAR T-Cell Therapy for Recurrent Glioblastoma
Targeting two brain tumor–associated proteins with chimeric antigen receptor (CAR) T-cell therapy may reduce solid tumor growth in patients with recurrent glioblastoma, according to results from a phase I trial published by Bagley et al in Nature Medicine. The findings suggest that the new...
Germ Cell Tumors: Survival Rates in Female vs Male Patients
Female patients with ovarian germ cell tumors may have worse prognoses compared with male patients with testicular germ cell tumors, according to a recent study published by Sköld et al in the Journal of Internal Medicine. Background Both ovarian and testicular germ cell tumors predominantly...
Neoadjuvant Therapy for EGFR-Positive Lung Adenocarcinoma
This is Part 3 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the neoadjuvant treatment ...
Management of Stage IIIA NSCLC in a Former Smoker
This is Part 2 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the management of stage...
Locally Advanced NSCLC
This is Part 1 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the management of locally ...
Cancer Prevalence in Europe as of 2020
In a study reported in The Lancet Oncology, De Angelis et al estimated the numbers of patients alive after a cancer diagnosis in Europe as of 2020. Study Details The study used data from the EUROCARE-6 study to estimate the prevalence of cancer in 29 European countries and the 27 countries in the ...
Metastatic Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Single-Agent Chemotherapy in Previously Treated Patients
As reported in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, and colleagues, final results of the phase III ASCENT trial showed continued superior progression-free and overall survival with sacituzumab govitecan-hziy, an anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug...
Sunitinib in Metastatic Progressive Pheochromocytomas and Paragangliomas
In a phase II trial (FIRSTMAPPP) reported in The Lancet, Eric Baudin, MD, and colleagues found that the multikinase inhibitor sunitinib was active in patients with metastatic progressive pheochromocytomas and paragangliomas. As stated by the investigators, “No randomized controlled trial has ever...
Immunotherapy Trials for Metastatic NSCLC: FDA Pooled Analysis
In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Bernardo Haddock Lobo Goulart, MD, and colleagues found that response rate and progression-free survival were only moderately correlated with overall survival in first-line immunotherapy trials for...
Risk Score to Assess Cardiovascular Complications in Hematopoietic Stem Cell Transplant Recipients
A novel tool may help predict the risk of complications following hematopoietic stem cell transplantation and guide the pretransplant process, according to new Scientific Statement published by Hayek et al in Circulation. The findings may also illuminate the contemporary prevalence of...
Collaborative Care Intervention May Benefit Patients With Cancer, Health-Care Systems
Adding specialized mental health support to the treatment plan of patients with cancer may improve their quality of life, lower the risk of cardiovascular disease in family caregivers, and boost cost savings to the health-care system, according to a recent study published by Steel et al in The...
HPV-Associated Oropharyngeal Cancer: Intratreatment FDG-PET Response as a Biomarker for De-escalation of Radiotherapy
The use of imaging midtreatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may guide the use of deintensified chemoradiotherapy, according to a phase II study from the University of Michigan presented by Regan et al at the 2024 Multidisciplinary Head and Neck...
Patients With Biochemical Recurrence of Prostate Cancer: Ga-68–RM2 PET-MRI vs MRI Alone for Lesion Detection
In a single-center phase II/III imaging trial reported in The Lancet Oncology, Duan and colleagues found that gallium Ga-68–labeled RM2 (Ga-68–RM2) positron-emission tomography (PET)-magnetic resonance imaging (MRI) outperformed MRI alone in positive findings and number of lesions detected in...
Variations in Use of Radiotherapy in Patients With Newly Diagnosed Common Cancers
In an International Cancer Benchmarking Partnership study reported in The Lancet Oncology, McPhail et al found wide interjurisdictional variation in the use of radiotherapy among patients with newly diagnosed common cancers in Norway, the United Kingdom, Canada, and Australia. Study Details The...
Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL: New Efficacy Analysis
A new matching adjusted indirect comparison of the efficacy of zanubrutinib vs acalabrutinib in relapsed or refractory chronic lymphocytic leukemia (CLL) based on data from the phase III ALPINE and ASCEND trials was presented by Shadman et al at the 28th Annual International Congress on Hematologic ...
Worsening Metabolic Syndrome May Increase Cancer Risk
Investigators may have identified a heightened risk of various types of cancers among patients with persistent and worsening metabolic syndrome, according to a recent study published by Deng et al in Cancer. Background Metabolic syndrome encompasses conditions such as high blood pressure, elevated...
Higher BMI May Be Linked to Complications Following Autologous Breast Reconstruction
Patients with a higher body mass index (BMI) may have a greater risk of overall and specific complications following autologous breast reconstruction, according to a recent study published by Barnes et al in Plastic and Reconstructive Surgery. Background Autologous breast reconstruction—an...
ASCO Chief Medical Officer Testifies to Congress About Ongoing Cancer Drug Shortage Crisis
On February 6, 2024, Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of the Association for Clinical Oncology (ASCO), testified before the full House Committee on Ways and Means on the crisis of ongoing cancer drug shortages. More than 15 cancer drugs continue...
ASCO and SSO Publish New Guideline on Germline Testing in Breast Cancer
ASCO in partnership with the Society of Surgical Oncology (SSO) has released a new guideline addressing recommendations in germline testing in patients with breast cancer.1 The guideline provides oncologists with a framework for how to approach germline testing and recommendations for who should be ...
Patricia LoRusso, DO, PhD (hc), Named the Amy and Joseph Perella Professor of Medicine at Yale School of Medicine
Patricia LoRusso, DO, PhD (hc), an internationally recognized expert in drug development and early-phase clinical investigation of novel cancer therapies, was recently appointed the Amy and Joseph Perella Professor of Medicine (medical oncology). The appointment is for a term of 10 years,...
Expert Point of View: Rachid Baz, MD
DREAMM-7, which evaluated belantamab mafodotin-blmf, bortezomib, and dexamethasone (BVd) in relapsed or refractory multiple myeloma, was discussed at the virtual session by Rachid Baz, MD, Myeloma Section Head and Co-Director of the Pentecost Family Myeloma Research Center at Moffitt Cancer Center, ...
ACCC Changes Name to Association of Cancer Care Centers
The Association of Community Cancer Centers (ACCC) is marking its 50th anniversary with a name change to illustrate the dynamic future of cancer care for its members. The largest advocacy and resource organization for multidisciplinary oncology professionals will now be known as the Association of...
